Top Markets
#1 Velas Velas +367.72%
#2 Gravity Gravity +51.70%
#3 Galxe Galxe +35.07%
#4 Derive Derive +30.68%
#5 Infinity Ground Infinity Ground +28.55%
#6 Fuzzybear Fuzzybear +21.27%
#7 Fetch.ai Fetch.ai +21.23%
#8 Wiki Cat Wiki Cat +21.09%
#9 Audiera Audiera +20.90%
#10 Aria.AI Aria.AI +20.59%
Coin of the day
Velas Velas
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Kedudukan dalam Saham #20716
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel... MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Harga Saham
$0.00001
Modal Pasaran
$50.01K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan MultiCell Technologies, Inc. (MCET)

Kategori

Healthcare
Permodalan Pasaran
Pendapatan
lagi
Keuntungan
Sejarah Harga
Nisbah P/E
Nisbah P/S
Nisbah P/B
Margin Operasi
EPS
Pecahan Saham
Dividen
Hasil Dividen
Saham Terbitan
Nisbah P/E bagi MultiCell Technologies, Inc. (MCET)
Nisbah P/E pada March 2026 TTM: -0.10
Menurut laporan kewangan dan harga saham terkini MultiCell Technologies, Inc., nisbah P/E semasa (TTM) ialah -0.10. Pada akhir 2013, syarikat mempunyai nisbah P/E sebanyak -1.09.
Sejarah nisbah P/E bagi MultiCell Technologies, Inc. dari 2013 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -0.10 -97.50%
2014 -3.92 260.77%
2013 -1.09 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -11,035.82%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -30,859.18%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -17,482.35%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -31,159.69%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -33,848.37%
AU
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.